Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Atrial Septal Defect Market Value Expansion And Long-Term Growth Outlook

The market encompassing atrial septal defect treatments experienced robust expansion recently. Projections indicate a rise from $4.46 billion in 2025 to $4.81 billion in 2026, fueled by a compound annual growth rate of 7.8%. This historical growth trend was propelled by enhanced identification of congenital heart anomalies, greater accessibility to surgical remediation methods, an increase in pediatric cardiology services, accumulating expertise in device-based closure procedures, and broader availability of advanced diagnostic imaging.

The market for atrial septal defect interventions is projected for substantial expansion, reaching an estimated $6.26 billion by 2030, reflecting a compound annual growth rate of 6.8%. This anticipated growth over the coming years stems from a confluence of factors including the greater utilization of hybrid closure methodologies, a heightened emphasis on intervening early in adult patients, the broadening scope of minimally invasive cardiac surgery, continuous innovation in the design of occluder devices, and a mounting need for solutions that support extended patient follow-up care. Key developments shaping this market during the forecast period are the increasing embrace of transcatheter closure devices, a discernible shift towards less invasive repair procedures, the wider application of sophisticated cardiac imaging technologies, the extension of screening programs for ASDs in both pediatric and adult populations, and a more concentrated effort on achieving favorable long-term patient results.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16345&type=smp

Atrial Septal Defect Market Development Factors: Which Trends Are Supporting Demand?

The escalating incidence of congenital heart defects (CHD), which are structural anomalies of the heart present from birth, is anticipated to be a significant catalyst for the expansion of the atrial septal defect market. These defects, characterized by abnormal formations in the heart’s structure at birth, are being identified with increasing frequency. Interventions for atrial septal defects play a crucial role in managing these congenital conditions by rectifying aberrant blood flow between the heart’s chambers, thereby enhancing cardiac performance and mitigating related health issues. Illustrating this trend, data from the British Heart Foundation, a UK charitable organization, indicated in September 2025 that 2.3 million individuals in the United Kingdom are currently living with congenital heart disease. Furthermore, approximately 1 in every 150 births in the UK results in the diagnosis of a congenital heart defect, equating to an average of 13 babies daily, with many diagnoses occurring later in life. It is estimated that the condition might affect between 1% and 2% of the general population. Consequently, the widespread occurrence of congenital heart defects is poised to stimulate growth within the atrial septal defect market.

Atrial Septal Defect Market Segment Analysis Highlighting Growth Areas

The atrial septal defect market covered in this report is segmented –

1) By Treatment Procedure: Surgical Closure, Transcatheter Closure, Hybrid Procedures, Medication Therapy

2) By Diagnosis: Chest X-Ray, Electrocardiogram, Cardiac Catheterization, Transesophageal Echocardiography, Pulse Oximetry

3) By Product Type: Medical Devices, Pharmaceutical Products

4) By Age Group: Pediatric, Adult

5) By End-User: Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, Other End-Users

Subsegments:

1) By Surgical Closure: Open Heart Surgery (Traditional Surgical Closure), Minimally Invasive Surgical Closure, Patches (Pericardial, Synthetic) For Asd Closure

2) By Transcatheter Closure: Device-Based Closure (Amplatzer Septal Occluder), Transcatheter Plug Closure Techniques, Catheter-Based Asd Repair For Adult And Pediatric Patients

3) By Hybrid Procedures: Combination Of Surgical And Transcatheter Techniques, Minimally Invasive Hybrid Procedures, Hybrid Closure For Complex Or Large Asds

4) By Medication Therapy: Anticoagulant Therapy (To Prevent Stroke), Diuretics (For Managing Symptoms), Antihypertensive Drugs (For Managing Associated Conditions), Off-Label Use Of Other Medications

Atrial Septal Defect Market Transformation Trends: Which Innovations Are Driving Change?

Leading entities within the atrial septal defect market are actively engaged in creating sophisticated devices and pursuing regulatory clearances to broaden their accessibility and applications. Gaining device approval signifies the attainment of official endorsement or validation for a medical device, generally from a governing agency or pertinent authority, preceding its lawful production, distribution, or deployment within a designated market or for a specific function. Illustrating this, in the month of March in the year 2024, Occlutech GmbH, a firm based in Sweden with expertise in minimally invasive cardiac devices, shared that the U.S. Food and Drug Administration (FDA) had granted its approval for the Occlutech ASD Occluder and the Occlutech Pistol Pusher, intended for the management of atrial septal defects (ASD). This regulatory endorsement represents a pivotal achievement for the company, which has been dedicated to enhancing healthcare worldwide. The Occlutech ASD Occluder is engineered to offer a permanent remedy for individuals diagnosed with defects confirmed through echocardiography. It is a self-expanding construct made of nitinol, comprising two pliable discs secured to each side of the patient’s atrial septum using the Occlutech Pistol Pusher delivery system. Following this approval, Occlutech is set to commence its sales efforts in the United States via a sole distribution agreement with B. Braun Interventional Systems.

Atrial Septal Defect Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Osypka AG, Cardia Inc, Gore Medical, Pfm Medical AG, Balton Sp. z o.o., Meril Life Sciences, TTK Healthcare, Braile Biomedica, Shanghai Shape Memory Alloy

Access The Complete Atrial Septal Defect Market Report:

https://www.thebusinessresearchcompany.com/report/atrial-septal-defect-global-market-report

#Atrial Septal Defect Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the atrial septal defect market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the atrial septal defect market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model